V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough
Biopharma & Life Sciences

Arcutis Biotherapeutics Executive Compensation (FY25)

ARQT · Executive and director compensation, fiscal 2023 to 2025
Data as of September 7, 2026Latest filing (8-K): June 9, 2026
283 figures on this page: 278 cited to the filing that reported them, 5 calculated from figures it prints. See the citations
Todd Franklin Watanabe was paid $7,223,065 in total compensation as President and Chief Executive Officer for fiscal 2025, and Watanabe's total was 95.8% higher than the $3,689,491 reported for fiscal 2024. The disclosed chief executive pay ratio for fiscal 2025 is 28:1, against median employee compensation of $262,613. Shareholders supported the say-on-pay proposal with 96.0% of votes cast for or against in favor at the meeting held June 5, 2026 for fiscal 2025. The disclosed peer group includes Agios Pharmaceuticals, AnaptysBio, Ardelyx, BioCryst Pharmaceuticals and Dynavax Technologies, among others.
Chief executive, fiscal 2025
◇
Todd Franklin Watanabe
Median of the other named officers
$2,118,203
5 officers, excluding the chief executive
Latest say-on-pay support
=
June 5, 2026
Chief executive pay ratio
◇
To the median employee
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Todd Franklin Watanabe: $3,689,491 → $7,223,065 (95.8% higher)
Say-on-pay support: 84.7% → 96.0% (11.3 points higher)
CEO pay ratio: 14:1 → 28:1 (100.0% higher)

Frequently asked questions

Answers drawn from the data on this page.
Who is Arcutis Biotherapeutics' chief executive and what were they paid?
Todd Franklin Watanabe was paid $7,223,065 in total compensation as President and Chief Executive Officer for fiscal 2025. Watanabe's total was 95.8% higher than the $3,689,491 reported for fiscal 2024.
What was Arcutis Biotherapeutics' say-on-pay result?
Shareholders supported the say-on-pay proposal with 96.0% of votes cast for or against in favor at the meeting held June 5, 2026 for fiscal 2025.
Which companies are in Arcutis Biotherapeutics' peer group?
The disclosed peer group includes Agios Pharmaceuticals, AnaptysBio, Ardelyx, BioCryst Pharmaceuticals and Dynavax Technologies, among others.
What is Arcutis Biotherapeutics' chief executive pay ratio?
The disclosed chief executive pay ratio for fiscal 2025 is 28:1, against median employee compensation of $262,613.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Todd Franklin Watanabe
President and Chief Executive Officer
◇—◇◇◇—◇◇
Patrick Burnett
Chief Medical Officer
◇—◇◇◇—◇◇
Masaru Matsuda
Chief Legal Officer
◇—◇◇◇—◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
David Topper
Former Chief Financial Officer
◇—◇◇◇—◇◇
Todd Franklin Watanabe
President and Chief Executive Officer
◇—◇◇◇—◇◇
Patrick Burnett
Chief Medical Officer
◇—◇◇◇—◇◇
L. Todd Edwards
Chief Commercial Officer
◇—◇◇◇—◇◇
Masaru Matsuda
Chief Legal Officer
◇—◇◇◇—◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Todd Franklin Watanabe
President and Chief Executive Officer
◇—◇◇◇—◇◇
L. Todd Edwards
Executive Vice President and Chief Commercial Officer
◇—◇◇◇—◇◇
Patrick Burnett
Executive Vice President and Chief Medical Officer
◇—◇◇◇—◇◇
Masaru Matsuda
Executive Vice President, Chief Legal Officer and Corporate Secretary
◇—◇◇◇—◇◇
David Topper
Former Chief Financial Officer
Departed during or after this year
◇—◇◇——◇◇
Latha Vairavan
Senior Vice President and Chief Financial Officer
◇—◇◇◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
David TopperRSU◇——◇——◇
David TopperOPTION◇——◇—◇◇
Latha VairavanRSU◇——◇——◇
Latha VairavanRSU◇——◇——◇
Latha VairavanOPTION◇——◇—◇◇
Latha VairavanOPTION◇——◇—◇◇
Patrick BurnettRSU◇——◇——◇
Patrick BurnettOPTION◇——◇—◇◇
Patrick BurnettRSU◇——◇——◇
Patrick BurnettOPTION◇——◇—◇◇
Todd FranklinOPTION◇——◇—◇◇
Todd FranklinRSU◇——◇——◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Todd Franklin WatanabeRSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇03/03/32
RSU◇◇——
Option◇—◇02/28/35
RSU◇◇——
Option◇—◇01/12/34
L. Todd EdwardsRSU◇◇——
Option◇—◇02/28/35
Option◇—◇01/12/34
RSU◇◇——
Option◇—◇02/28/35
RSU◇◇——
RSU◇◇——
Patrick BurnettRSU◇◇——
Option◇—◇02/28/35
Option◇—◇02/28/35
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇—
Masaru MatsudaOption◇—◇02/28/35
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Latha VairavanRSU◇◇——
Option◇—◇01/12/34
RSU◇◇——
Option◇—◇02/28/35
RSU◇◇——
RSU◇◇——
Option◇—◇03/02/33
RSU◇◇——
RSU◇◇——
Option◇—◇01/12/34
Option◇—◇05/06/35
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Amit D. Munshi
◇◇◇———◇
Keith R. Leonard
Board chair
◇◇◇———◇
Sue-Jean Lin
◇◇◇———◇
Bhaskar Chaudhuri
◇◇◇———◇
Neha Krishnamohan
◇◇◇———◇
Terrie Curran
◇◇◇———◇
Halley Gilbert
◇◇◇———◇
Patrick J. Heron
◇◇◇———◇
Howard G. Welgus
◇◇◇———◇
Todd Franklin Watanabe served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Total board retainer◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇
Equity is delivered as Options and RSUs.

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • Agios Pharmaceuticals AGIO
  • AnaptysBio ANAB
  • Ardelyx ARDX
  • BioCryst Pharmaceuticals BCRX
  • Dynavax Technologies DVAX
  • Evolus EOLS
  • MannKind Corporation MNKD
  • Mirum Pharmaceuticals MIRM
  • Ocular Therapeutics OCUL
  • Phathom Pharmaceuticals PHAT
  • Protagonist Therapeutics PTGX
  • Sage Therapeutics SAGE
  • Tarsus Pharmaceuticals TARS
  • Travere Therapeutics TVTX
  • Vanda Pharmaceuticals VNDA
  • Vericel VCEL
  • Y-mAbs Therapeutics YMAB

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025June 5, 2026=◇◇◇
2024June 12, 2025=◇◇◇
2023June 14, 2024=◇◇◇
2022May 31, 2023=◇◇◇
2021June 1, 2022=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇
Email me this page as a cited PDF
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Arcutis Biotherapeutics files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Arcutis Biotherapeutics disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Arcutis Biotherapeutics sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Enquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for a Velarion Pro seat
Full platform access for one person: every industry we cover, peer positioning, and the written analysis. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.
Join the list for Peer Group Review
Whether Arcutis Biotherapeutics' disclosed peer group is defensible, who names Arcutis Biotherapeutics back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
283 figures on this page: 278 cited to the filing that reported them, 5 calculated from figures it prints.
278 cited to the filing
5 calculated from the filing

Documents cited

  1. 0001628280-26-041883
    Item 5.07 Submission of Matters to a Vote of Security Holders
  2. 0001787306-26-000028
    2025 Summary Compensation Table · CEO Pay Ratio · Director Compensation · Director Compensation Table · and 2 more sections
  3. 0001787306-25-000096
    Item 5.07 Submission of Matters to a Vote of Security Holders
  4. 0001787306-25-000069
    2024 Summary Compensation Table
  5. 0001787306-24-000090
    Item 5.07 Submission of Matters to a Vote of Security Holders
  6. 0001787306-24-000061
    Summary Compensation Table
  7. 0001787306-23-000068
    Item 5.07 Submission of Matters to a Vote of Security Holders
  8. 0001787306-22-000038
    Item 5.07 Submission of Matters to a Vote of Security Holders
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Arcutis Biotherapeutics executive compensation, FY2023–FY2025.” https://intel.velarion.ai/comp/ARQT (accessed 2026).
Short form: data: Velarion
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Arcutis Biotherapeutics and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Peers Arcutis Biotherapeutics discloses

The companies named in ARQT's own disclosed peer group.

Agios PharmaceuticalsArdelyxEvolusMirum PharmaceuticalsPhathom PharmaceuticalsProtagonist TherapeuticsTravere TherapeuticsVanda PharmaceuticalsVericel

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  The Pay Desk · Methodology · Terms · Privacy